论文部分内容阅读
目的评价双环醇治疗慢性乙型肝炎的临床疗效。方法选择60例HBsAg,HBeAg,anti-HBc及HBVDNA均为阳性的慢性乙型肝炎患者,随机分成治疗组30例,予双环醇50mg,po,tid,服用3个月后减量至25mg,po,tid,疗程共6个月;对照组30例,予甘力欣胶囊150mg,po,tid,疗程6个月。结果治疗结束时,治疗组ALT复常率96.7%,对照组40%,有显著差异(P<0.01);而HBeAg、HBVDNA的阴转率治疗组分别为46.7%、60%,对照组为10%、20%,治疗组优于对照组(P<0.05)。结论双环醇是治疗慢性乙型肝炎较理想的保肝抗病毒药物。
Objective To evaluate the clinical efficacy of bicyclol in the treatment of chronic hepatitis B. Methods Sixty patients with chronic hepatitis B who were positive for HBsAg, HBeAg, anti-HBc and HBVDNA were randomly divided into treatment group (n = 30) and bicyclol 50 mg, po, tid. After three months, the dosage was reduced to 25 mg , tid, a total of 6 months treatment; control group of 30 cases, to Gan Lixin capsule 150mg, po, tid, treatment for 6 months. Results At the end of treatment, the ALT normalization rate was 96.7% in the treatment group and 40% in the control group (P <0.01), while the negative conversion rate of HBeAg and HBVDNA was 46.7% and 60% in the treatment group and 10% in the control group %, 20%, the treatment group than the control group (P <0.05). Conclusion Bicyclol is an ideal hepatoprotective drug for the treatment of chronic hepatitis B.